Company Milestones
Zydus currently offers over 80 FDA-approved generic products across a wide variety of therapeutic categories in the US. To learn more about our history, select one of the time frames below.
1950s – 1960s – Cadila made a mark with innovative medicines such as Livirubra, the first of its kind in India to treat pernicious anemia
1952 – Cadila Laboratories Ltd. established by Mr. Ramanbhai B. Patel
1970s – 1980s – Cadila became a benchmark for Quality and Excellence
1995-1996 – Acquired Indo Pharma Pharmaceutical Works Ltd – the group’s first acquisition
1995-1996 – Launched 23 new products in 1995, with first-in-India like Falcigo
1995-1996 – Zydus’s journey began with Rs 250 crs.
1997-1998 – Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV
1999-2000 – Entered into capital markets through Initial Public Offering (IPO)
1999-2000 – Entered into JV with Sarabhai for consolidating its position in Animal Healthcare
2000-2001 – Acquired Recon Healthcare, which boosted Zydus’s strengths in southern markets
2000-2001 – Zydus Research Centre set up at Moraiya
2000-2002 – Acquired German Remedies – the largest M&A in the Indian pharmaceutical sector at the time
2001-2002 – Acquired Aten and attained the top spot in the cardiovascular segment in India
2001-2002 – Acquired USFDA approved API plant,
Banyan Chemicals
2002-2003 – Zydus Pharmaceuticals (USA) Inc. incorporated
2003-2004 – Acquired Alpharma France (renamed Zydus France) – Zydus’s first international acquisition
2004-2005 – Filed first IND in India for ZYH11
2005-2006 – Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd
2006-2007 – Acquired Liva Healthcare and entered the dermatology market in India
2006-2007 – Acquired Nippon Universal and entered the Japanese market
2007-2008 – Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda
2008-2009 – Acquired Laboratorios Combix in Spain, Simayla Pharma in South America, and Etna Biotech in Italy
2009-2010 – Launched first formulation using nano-technology platform in India – Oxalgin Nanogel
2010-2011 – Achieved $1 billion in sales
2010-2011 – Entered into a 50:50 JV with Bayer to set up a new marketing company
2010-2011 – Entered into strategic agreement with Abbott for commercializing branded generics in emerging markets
2010-2011 – Launched Vaxiflu – S, India’s first H1N1 vaccine
2011-2012 – Acquired 100% stake in Biochem, one of the top 40 pharma companies in India
2011-2012 – Acquired Bremer Pharma GmbH to gain a global footprint in the animal healthcare business
2011-2012 – Acquired the assets of US-based Nesher Pharmaceuticals Inc.
2011-2012 – Received USFDA approval of Baddi manufacturing plant
2012-2013 – Over 114 new products launched during the year, 31 of which were first in India launches
2013 – Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes
2014 – Zydus launched world’s first biosimilar of adalimumab
2015 – Zydus began Phase III study of saroglitazar in NASH
2016 – Zydus acquired Zoetis, a global animal health company
2016 – Zydus and Takeda entered into partnership to address emerging infection diseases
2016 – Zydus began supplying product in the US market from its SEZ facility
2016 – Zydus received approval from the USFDA to initiate Phase II clinical trials of saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in the US
2016 – Zydus’s Nesher Pharmaceuticals received its first ANDA approval, dextroamphetamine tablets
2017 – Zydus Cadila acquired Sentynl Therapeutics Inc., US-based specialty company
2017 – Zydus launched India’s first Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4
2017 – Zydus received regulatory approval of LipaglynTM in Mexico
2017 – Zydus received USFDA approval to initiate Phase II clinical studies of saroglitazar in patients with Primary Biliary Cholangitis (PBC)
2017 – Zydus started Phase II trial of ZYAN1 for treating anemia in patients with CKD
2018 – Cadila Healthcare acquired 51% stake in Windlas Healthcare
2018 – Zydus partnered with Medicure to launch its NDA product, ZYPITAMAG
2019 – Zydus received USFDA approval for its first transdermal product, rivastigmine transdermal system.
2019 – Zydus Wellness Ltd. completed the acquisition of Heinz India Private Limited.
2020 – Zydus began supplying product in the US market from its Liva facility.
2020 – Cadila Healthcare Ltd. received USFDA approval to initiate clinical trials of desidustat in chemotherapy induced anemia (CIA).
2020 – Zydus granted fast track designation by USFDA for Saroglitazar Mg in the treatment of patients with Primary Biliary Cholangitis (PBC).
2021 – Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar Mg in the treatment of patients with Primary Biliary Cholangitis (PBC).
2021 – Zydus Cadila’s ZyCoV-D vaccine, the first plasmid DNA vaccine to be approved for human use in the world, was granted Emergency Use Authorization in India for adults and children 12 years and above.
2022 – Cadila Healthcare Limited rebranded to Zydus Lifesciences Limited. The company’s new brand identity brings together two hearts in purple and teal colors symbolizing its commitment to science and innovation along with care and nurturance.